Vigabatrin (VGB) administered during late gestation lowers maternal folate concentration and causes pregnancy loss, fetal growth restriction and skeletal hypoplasia in the mouse.

@article{Padmanabhan2010VigabatrinA,
  title={Vigabatrin (VGB) administered during late gestation lowers maternal folate concentration and causes pregnancy loss, fetal growth restriction and skeletal hypoplasia in the mouse.},
  author={R. Padmanabhan and Y. Abdulrazzaq and S. Bastaki and M. Nurulain and M. Shafiullah},
  journal={Reproductive toxicology},
  year={2010},
  volume={29 3},
  pages={
          366-77
        }
}
Vigabatrin (VGB) has several therapeutic advantages over older antiepileptic drugs (AED), but there is a lack of information about its potential reproductive toxicologic effects. Our aim was to evaluate the consequences of VGB administered during late gestation on fetal growth and development in the mouse. Based on the results of our previous study, we administered groups of mice a single dose of 450 mg/kg VGB on one of gestation days (GD) 15, 16 or 17. Fetuses were collected on GD 18. VGB… Expand

References

SHOWING 1-10 OF 87 REFERENCES
Teratogenicity of sodium valproate
Folate and human reproduction.
...
1
2
3
4
5
...